NASDAQ:ANGN Angion Biomedica Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Angion Biomedica Corp. Please log in to your account or sign up in order to add this asset to your watchlist. $1.10 -0.02 (-1.79%) (As of 07/5/2022 10:48 AM ET) Add Compare Share Today's Range$1.10▼$1.1250-Day Range$1.10▼$2.0252-Week Range$1.03▼$14.18Volume5,536 shsAverage Volume304,010 shsMarket Capitalization$32.96 millionP/E RatioN/ADividend YieldN/APrice Target$41.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Angion Biomedica MarketRank™ ForecastAnalyst RatingHold2.33 Rating ScoreUpside/Downside1,431.5% Upside$17.00 Price TargetShort InterestHealthy4.75% of Float Sold ShortDividend StrengthN/ASustainability-0.73Upright™ Environmental ScoreNews Sentiment-0.01Based on 15 Articles This WeekInsider TradingAcquiring Shares$109,949 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($1.87) to ($1.82) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.2.19 out of 5 starsMedical Sector195th out of 1,428 stocksPharmaceutical Preparations Industry86th out of 680 stocks 3.2 Analyst's Opinion Consensus RatingAngion Biomedica has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $17.00, Angion Biomedica has a forecasted upside of 1,431.5% from its current price of $1.11.Amount of Analyst CoverageAngion Biomedica has only been the subject of 3 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted4.75% of the float of Angion Biomedica has been sold short.Short Interest Ratio / Days to CoverAngion Biomedica has a short interest ratio ("days to cover") of 5.5.Change versus previous monthShort interest in Angion Biomedica has recently decreased by 10.46%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAngion Biomedica does not currently pay a dividend.Dividend GrowthAngion Biomedica does not have a long track record of dividend growth. Previous Next 4.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAngion Biomedica has received a 75.65% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physiological diseases " and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Angion Biomedica is -0.73. Previous Next 1.7 News and Social Media Coverage News SentimentAngion Biomedica has a news sentiment score of -0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for Angion Biomedica this week, compared to 1 article on an average week.Search Interest8 people have searched for ANGN on MarketBeat in the last 30 days. This is an increase of 167% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Angion Biomedica to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Angion Biomedica insiders have bought more of their company's stock than they have sold. Specifically, they have bought $109,949.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders19.70% of the stock of Angion Biomedica is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 23.43% of the stock of Angion Biomedica is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Angion Biomedica are expected to grow in the coming year, from ($1.87) to ($1.82) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Angion Biomedica is -1.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Angion Biomedica is -1.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAngion Biomedica has a P/B Ratio of 0.41. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ANGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Angion Biomedica and its competitors with MarketBeat's FREE daily newsletter. Email Address About Angion Biomedica (NASDAQ:ANGN) StockAngion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company's lead product candidate is ANG-3070, an oral tyrosine kinase receptor inhibitor in development as a treatment for fibrotic diseases, primarily in the kidney and lung. It also develops ANG-3777, a hepatocyte growth factor mimetic to treat acute organ injuries, such as delayed graft function; ROCK2 inhibitors programs for fibrotic diseases; and CYP11B2 inhibitor program. The company was incorporated in 1998 and is based in Uniondale, New York.Read More ANGN Stock News HeadlinesJuly 5, 2022 | americanbankingnews.comAngion Biomedica Corp. Forecasted to Post Q2 2022 Earnings of ($0.42) Per Share (NASDAQ:ANGN)July 1, 2022 | morningstar.comAngion Biomedica Corp Ordinary Shares - Stock Quote ANGNJuly 5, 2022 | Investing Trends (Ad)Biden: By 2030, 50% Of All Vehicles Will Be Electric. Sparking New "Lithium Gold Rush."Experts predict that the global lithium market will balloon by 500%. That's wonderful news for investors, because a "sure-thing" like this appears once in a lifetime. And this small-cap company just snagged what could be one of the world's largest lithium deposits.July 1, 2022 | marketwatch.comAngion Biomedica Shares Plumb New Depths After Study Setback >ANGNJuly 1, 2022 | americanbankingnews.comStifel Nicolaus Downgrades Angion Biomedica (NASDAQ:ANGN) to HoldJune 30, 2022 | finance.yahoo.comAngion Biomedica Pulls The Plug On Another Kidney Disease Trial - Read WhyJune 30, 2022 | americanbankingnews.comOppenheimer Lowers Angion Biomedica (NASDAQ:ANGN) to Market PerformJune 29, 2022 | finance.yahoo.comAngion Biomedica shares dive after kidney-disease drug trial discontinuedJuly 5, 2022 | Investing Trends (Ad)Biden: By 2030, 50% Of All Vehicles Will Be Electric. Sparking New "Lithium Gold Rush."Experts predict that the global lithium market will balloon by 500%. That's wonderful news for investors, because a "sure-thing" like this appears once in a lifetime. And this small-cap company just snagged what could be one of the world's largest lithium deposits.June 29, 2022 | finance.yahoo.comAngion Announces Discontinuation of Phase 2 Trial of ANG-3070 in Patients with Primary Proteinuric Kidney DiseaseJune 29, 2022 | seekingalpha.comAngion to discontinue phase 2 trial of ANG-3070 in patients with kidney diseaseMay 28, 2022 | finance.yahoo.comJay Venkatesan Is The President of Angion Biomedica Corp. (NASDAQ:ANGN) And They Just Picked Up 5.7% More SharesMay 16, 2022 | finance.yahoo.comAngion Provides Corporate Update and Reports First Quarter 2022 Financial ResultsMay 16, 2022 | finance.yahoo.comAngion Announces Phase 1b Trial of ANG-3070 in Patients with Idiopathic Pulmonary FibrosisMay 11, 2022 | finance.yahoo.com5 Biotech Stocks Set to Outpace Q1 Earnings EstimatesMay 6, 2022 | finance.yahoo.comHere's Why We're Watching Angion Biomedica's (NASDAQ:ANGN) Cash Burn SituationApril 14, 2022 | finance.yahoo.comAngion Announces Participation in Upcoming Investment ConferenceApril 1, 2022 | seekingalpha.comAngion Biomedica GAAP EPS of -$1.93, revenue of $28.31MMarch 30, 2022 | finance.yahoo.comAngion Provides Corporate Update and Reports Full Year 2021 Financial ResultsMarch 15, 2022 | msn.comPrecision BioSciences (DTIL) Reports Q4 Loss, Misses Revenue EstimatesMarch 10, 2022 | nasdaq.comEvogene (EVGN) Reports Q4 Loss, Tops Revenue EstimatesMarch 6, 2022 | finance.yahoo.comShareholders in Angion Biomedica (NASDAQ:ANGN) are in the red if they invested a year agoFebruary 28, 2022 | finance.yahoo.comAngion Announces Participation in Upcoming Investment ConferencesJanuary 24, 2022 | nasdaq.comAngion Biomedica Corp. Common Stock (ANGN)January 5, 2022 | finance.yahoo.comTrade Alert: The President Of Angion Biomedica Corp. (NASDAQ:ANGN), Jay Venkatesan, Has Just Spent US$730k Buying 24% More SharesJanuary 4, 2022 | finance.yahoo.comAngion Provides Corporate Update and Announces Participation in Upcoming Investor ConferenceDecember 30, 2021 | nasdaq.comThursday 12/30 Insider Buying Report: ANGN, PLLSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ANGN CUSIPN/A CIK1601485 Webwww.angion.com Phone415-655-4899FaxN/AEmployees72Year FoundedN/ACompany Calendar Last Earnings5/16/2022Today7/05/2022Next Earnings (Estimated)8/11/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$17.00 High Stock Price Forecast$28.00 Low Stock Price Forecast$8.00 Forecasted Upside/Downside+3,627.3%Consensus RatingHold Rating Score (0-4)2.33333333333333 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-54,570,000.00 Net Margins-108.57% Pretax Margin-108.57% Return on Equity-44.25% Return on Assets-31.11% Debt Debt-to-Equity RatioN/A Current Ratio7.34 Quick Ratio7.34 Sales & Book Value Annual Sales$28.31 million Price / Sales1.16 Cash FlowN/A Price / Cash FlowN/A Book Value$2.72 per share Price / Book0.40Miscellaneous Outstanding Shares29,960,000Free Float24,057,000Market Cap$32.96 million OptionableNot Optionable Beta0.82 Angion Biomedica Frequently Asked Questions Should I buy or sell Angion Biomedica stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Angion Biomedica in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Angion Biomedica stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ANGN, but not buy additional shares or sell existing shares. View analyst ratings for Angion Biomedica or view top-rated stocks. What is Angion Biomedica's stock price forecast for 2022? 3 Wall Street analysts have issued twelve-month price objectives for Angion Biomedica's stock. Their ANGN stock forecasts range from $8.00 to $28.00. On average, they expect Angion Biomedica's share price to reach $17.00 in the next twelve months. This suggests a possible upside of 1,417.9% from the stock's current price. View analysts' price targets for Angion Biomedica or view top-rated stocks among Wall Street analysts. How has Angion Biomedica's stock performed in 2022? Angion Biomedica's stock was trading at $2.90 on January 1st, 2022. Since then, ANGN shares have decreased by 61.4% and is now trading at $1.12. View the best growth stocks for 2022 here. When is Angion Biomedica's next earnings date? Angion Biomedica is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022. View our earnings forecast for Angion Biomedica. How were Angion Biomedica's earnings last quarter? Angion Biomedica Corp. (NASDAQ:ANGN) issued its earnings results on Monday, May, 16th. The company reported ($0.48) EPS for the quarter, missing analysts' consensus estimates of ($0.44) by $0.04. The business earned $1.65 million during the quarter, compared to analysts' expectations of $1.23 million. Angion Biomedica had a negative trailing twelve-month return on equity of 44.25% and a negative net margin of 108.57%. View Angion Biomedica's earnings history. Who are Angion Biomedica's key executives? Angion Biomedica's management team includes the following people: Dr. Jay R. Venkatesan M.B.A., M.D., Ph.D., Pres, CEO & Chairman (Age 50, Pay $587.1k)Dr. John F. Neylan M.D., Exec. VP, Chief Medical Officer, & Head of Research (Age 69, Pay $468.65k)Mr. Gregory S. Curhan, Chief Financial Officer (Age 60)Ms. Jennifer J. Rhodes J.D., Exec. VP, Chief Bus. Officer, Gen. Counsel, Chief Compliance Officer & Sec. (Age 52) (LinkedIn Profile)Mr. Daniel Iazzetti, VP of HRBruce Rich, Assistant Sec. Who are some of Angion Biomedica's key competitors? Some companies that are related to Angion Biomedica include scPharmaceuticals (SCPH), Immuneering (IMRX), IO Biotech (IOBT), Citius Pharmaceuticals (CTXR), ProMetic Life Sciences (PFSCF), Puma Biotechnology (PBYI), Nanobiotix (NBTX), NextCure (NXTC), ContraFect (CFRX), Humanigen (HGEN), CytomX Therapeutics (CTMX), LumiraDx (LMDX), ESSA Pharma (EPIX), Longeveron (LGVN) and MediciNova (MNOV). View all of ANGN's competitors. When did Angion Biomedica IPO? (ANGN) raised $75 million in an initial public offering on Friday, February 5th 2021. The company issued 5,000,000 shares at $14.00-$16.00 per share. Cowen and Stifel served as the underwriters for the IPO and H.C. Wainwright & Co., LLC and Oppenheimer & Co. were co-managers. What is Angion Biomedica's stock symbol? Angion Biomedica trades on the NASDAQ under the ticker symbol "ANGN." How do I buy shares of Angion Biomedica? Shares of ANGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Angion Biomedica's stock price today? One share of ANGN stock can currently be purchased for approximately $1.12. How much money does Angion Biomedica make? Angion Biomedica (NASDAQ:ANGN) has a market capitalization of $33.56 million and generates $28.31 million in revenue each year. The company earns $-54,570,000.00 in net income (profit) each year or ($1.01) on an earnings per share basis. How many employees does Angion Biomedica have? Angion Biomedica employs 72 workers across the globe. How can I contact Angion Biomedica? Angion Biomedica's mailing address is 51 Charles Lindbergh Boulevard, Uniondale NY, 11553. The official website for Angion Biomedica is www.angion.com. The company can be reached via phone at 415-655-4899 or via email at daniel@lifesciadvisors.com. This page (NASDAQ:ANGN) was last updated on 7/5/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
